Skip to main content

Table 4 Combined genotypes of RRM2 and E2F1 polymorphisms and chemotherapy sensitivity in AML patients

From: Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)

rs1130609 rs3213150 CR, n (%) Non-CR, n (%) P OR (95% CI) P b OR (95% CI)b
TT+GT CC+CT 158 (66.7%) 79 (33.3%)   1.00 (reference)   1.00 (reference)
TT+GT TT 20 (54.1%) 17 (45.9%) 0.134 1.700 (0.844–3.426) 0.048 2.115 (1.006–4.450)
GG CC+CT 13 (48.1%) 14 (51.9%) 0.056 2.154 (0.966–4.802) 0.159 1.840 (0.787–4.301)
GG TT 1 (16.7%) 5 (83.3%) 0.004 10.00 (1.149–87.06) 0.041 9.780 (1.099–87.069)
Unfavorable combinationsa 34 (48.6%) 36 (51.4%) 0.006 2.118 (1.233–3.637) 0.005 2.257 (1.273–4.002)
  1. aUnfavorable combination genotypes included rs1130609 GG genotype or rs3213150 TT genotype
  2. bAdjusted by age, risk stratification, WBC count, and serum LDH level